Triplebar’s Latest $20M Financing Will Expand Its Product Portfolio Across Food and Biopharmaceuticals
Triplebar announced $20M in new funding to expand its product portfolio in food and biopharmaceuticals.
- Triplebar announced $20M in new funding to expand its product portfolio in food and biopharmaceuticals.
- Triplebar’s Hyper-Throughput™ screening platform acts as a “microprocessor for biology,” integrating hardware, software, biology and biochemistry to miniaturize and accelerate evolution.
- “Our investors believe profoundly in our mission to reduce humanity’s footprint while greatly increasing our quality of life with better food and biopharmaceuticals,” said Triplebar CEO Maria Cho.
- “For truly disruptive adoption to take place, alternative products need to at least match animal-based proteins on taste, price, convenience, and nutrition.